Risk of multiple sclerosis following clinically isolated syndrome: A 4-year prospective study

Journal of Neurology

Volumn 260, Issue 6, 2013, Pages 1583-1593

  D'Alessandro, Roberto ^a   Vignatelli, Luca ^a,b   Lugaresi, Alessandra ^c   Baldin, Elisa ^a,o   Granella, Franco ^d   Tola, Maria Rosaria ^e   Malagù, Susanna ^f   Motti, Luisa ^g   Neri, Walter ^h   Galeotti, Massimo ⁱ   Santangelo, Mario ^j   Fiorani, Laila ⁱ   Montanari, Enrico ^k   Scandellari, Cinzia ^l   Benedetti, Maria Donata ^m   Leone, Maurizio ⁿ  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b City of Bologna Local Health Trust   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UO Neurologia   (Italy)

^f BUFALINI HOSPITAL   (Italy)

^g Neurologia   (Italy)

^h Emergency Medicine   (Italy)

ⁱ SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^j Ospedale Ramazzini   (Italy)

^k Vaio Fidenza Hospital   (Italy)

^l IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^m Azienda Ospedaliera Universitaria Integrata   (Italy)

ⁿ MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^o Department of Epidemiology   (United States)

more..

Author keywords

Clinically isolated syndrome; Cohort studies; Multiple sclerosis; Natural history studies; Prognosis

Indexed keywords

PLACEBO;

ADULT; ARTICLE; COHORT ANALYSIS; DEMYELINATING DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; COHORT STUDIES; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84878819398     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6838-x     Document Type: Article

References (29)

1. Sastre-Garriga J, Tintore M, Rovira A et al (2003) Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 9(1):39-43 (Pubitemid 36253695)
2. Miller D, Barkhof F, Montalban X et al (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4(5):281-288 (Pubitemid 40545039)
3. Beck RW, Chandler DL, Cole SR et al (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51(4):481-490 (Pubitemid 34260778)
4. Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227-231 (Pubitemid 13158528)
5. Tintore M, Rovira A, Arrambide G et al (2010) Brainstem lesions in clinically isolated syndromes. Neurology 75(21):1933-1938
6. Paolino E, Fainardi E, Ruppi P et al (1996) A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 60(5):572-575 (Pubitemid 26147901)
7. Sormani MP, Tintore M, Rovaris M et al (2008) Will Rogers phenomenon in multiple sclerosis. Ann Neurol 64(4):428-433
8. Morrissey SP, Miller DH, Kendall BE et al (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116(Pt 1):135-146 (Pubitemid 23087039)
9. Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576-1582 (Pubitemid 32488815)
10. Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242-1249 (Pubitemid 44563835)
11. Comi G, De Stefano N, Freedman MS, et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11(1):33-41
12. Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503-1511
13. Rojas JI, Patrucco L, Cristiano E (2010) Oligoclonal bands and MRI in Clinically Isolated Syndromes: predicting conversion time to multiple sclerosis. J Neurol 257(7):1188-1191
14. Korteweg T, Tintore M, Uitdehaag B et al (2006) MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5(3):221-227 (Pubitemid 43238345)
15. Chard DT, Dalton CM, Swanton J et al (2011) MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 82(2):176-179
16. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444-1452 (Pubitemid 14237132)
17. Fischer JS, Rudick RA, Cutter GR et al (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5(4):244-250 (Pubitemid 29405620)
18. Solari A, Radice D, Manneschi L et al (2005) The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 228(1):71-74 (Pubitemid 39656497)
19. Kalkers NF, Bergers L, de Groot V et al (2001) Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 56(2):215-219 (Pubitemid 32095363)
20. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-127 (Pubitemid 32591472)
21. Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58(6):840-846 (Pubitemid 41746873)
22. Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059-2069 (Pubitemid 27493740)
23. Tintore M, Rovira A, Martinez MJ et al (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21(4):702-706 (Pubitemid 30210434)
24. Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292-302
25. Rocca MA, Agosta F, Sormani MP et al (2008) A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 255(5):683-691
26. McAlpine D (1972) Multiple sclerosis: a re-appraisal. In: Acheson ED (ed) McAlpine D LC. The problem of diagnosis. Churchill Livingstone, Edinburgh, pp 142-178
27. Tintoré M, Rovira A, Río J (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67:968-972 (Pubitemid 44454586)
28. Feuillet L, Reuter F, Audoin B et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13(1):124-127 (Pubitemid 46152771)
29. Mattarozzi K, Vignatelli L, Baldin E et al (2012) Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. Int J Clin Pract 66(5):504-514